Unichem Laboratories (UNICHEMLAB)₹509.15+1.30%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Unichem Laboratories reported sales of ₹632 Cr, up 20.0% from Jun 2025, and net profit of ₹41.08 Cr. For the year to Mar 2026, sales were ₹2,200 Cr and net profit ₹253 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 416 | 465 | 432 | 483 | 506 | 533 | 586 | 527 | 578 | 520 | 574 | 632 |
| Expenses | 408 | 436 | 407 | 445 | 454 | 450 | 505 | 506 | 515 | 478 | 529 | 566 |
| Operating Profit | 8.99 | 30.96 | 24.94 | 39.94 | 54.93 | 85.91 | 83.82 | 21.95 | 65.91 | 44.90 | 47.89 | 69.84 |
| OPM % | 2.1% | 7.0% | 6.0% | 8.0% | 11.0% | 16.0% | 14.0% | 4.3% | 11.0% | 9.0% | 8.0% | 11.0% |
| Other Income | 5.99 | 78.81 | −119 | 3.99 | 8.98 | 13.97 | 8.99 | 6.99 | −36.94 | 287 | 10.98 | 15.97 |
| Interest | 6.99 | 5.99 | 4.99 | 3.99 | 4.99 | 6.99 | 4.99 | 6.99 | 7.99 | 6.99 | 8.98 | 6.99 |
| Depreciation | 29.08 | 32.11 | 27.08 | 32.11 | 32.10 | 31.07 | 30.09 | 32.10 | 31.06 | 31.11 | 31.08 | 30.07 |
| Profit before tax | −22.05 | 73.14 | −126 | 8.02 | 27.07 | 62.13 | 58.17 | −9.02 | −11.03 | 294 | 19.03 | 49.16 |
| Tax % | 12.0% | 0.0% | 3.0% | 73.9% | 8.9% | 6.0% | 8.0% | 15.9% | 9.9% | 10.0% | 41.9% | 15.0% |
| Exceptional items | 0.00 | 66.06 | −122 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −57.03 | 247 | −7.01 | 0.00 |
| Net Profit | −24.02 | 73.08 | −129 | 2.01 | 25.02 | 58.05 | 53.09 | −10.01 | −12.02 | 264 | 11.01 | 41.08 |
| EPS (Rs) | −3.49 | 10.42 | −18.42 | 0.30 | 3.51 | 8.23 | 7.53 | −1.50 | −1.70 | 37.59 | 1.56 | 5.90 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,330 | 697 | 814 | 1,178 | 1,102 | 1,233 | 1,269 | 1,340 | 1,783 | 2,107 | 2,200 | 2,304 |
| Expenses | 1,174 | 741 | 946 | 1,260 | 1,157 | 1,148 | 1,202 | 1,394 | 1,704 | 1,852 | 2,022 | 2,088 |
| Operating Profit | 164 | −40.91 | −128 | −73.84 | −48.92 | 90.86 | 71.88 | −45.90 | 86.80 | 264 | 189 | 229 |
| OPM % | 12.0% | −6.0% | −16.0% | −6.0% | −4.5% | 7.0% | 6.0% | −3.4% | 4.9% | 13.0% | 9.0% | 9.9% |
| Other Income | 14.98 | 184 | 2,731 | 90.88 | 90.91 | 49.91 | 46.94 | 0.00 | −25.97 | 34.97 | 260 | 277 |
| Interest | 2.99 | 2.99 | 7.99 | 7.99 | 7.99 | 4.99 | 5.99 | 16.98 | 22.97 | 20.97 | 31.94 | 30.95 |
| Depreciation | 39.13 | 44.10 | 51.11 | 67.19 | 82.20 | 84.27 | 91.31 | 113 | 123 | 125 | 125 | 123 |
| Profit before tax | 137 | 97.30 | 2,553 | −58.13 | −48.12 | 51.11 | 22.06 | −176 | −85.27 | 155 | 293 | 351 |
| Tax % | 20.9% | −12.1% | 0.0% | −59.0% | 24.9% | 32.9% | −50.0% | 15.0% | 9.9% | 10.9% | 13.9% | — |
| Exceptional items | 0.00 | 1.01 | 9.01 | 18.01 | 26.01 | 8.01 | 2.01 | −24.04 | −50.01 | 1.01 | 171 | 183 |
| Net Profit | 108 | 109 | 2,549 | −24.01 | −60.10 | 34.02 | 33.02 | −202 | −94.10 | 138 | 253 | 304 |
| EPS (Rs) | 11.93 | 11.98 | 362.53 | −3.39 | −8.57 | 4.88 | 4.71 | −28.77 | −13.35 | 19.56 | 35.97 | 43.35 |
| Dividend payout % | 17.0% | 25.0% | 1.0% | −118.0% | −47.0% | 82.0% | 85.0% | −14.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17.99 | 17.99 | 17.97 | 14.01 | 13.99 | 14.00 | 13.98 | 13.99 | 13.98 | 13.98 | 13.98 | 14.00 |
| Reserves | 850 | 937 | 1,047 | 2,669 | 2,610 | 2,519 | 2,547 | 2,608 | 2,423 | 2,426 | 2,440 | 2,706 |
| Borrowings | 22.03 | 36.03 | 98.02 | 151 | 200 | 206 | 119 | 349 | 314 | 248 | 460 | 500 |
| Other Liabilities | 264 | 282 | 357 | 358 | 321 | 405 | 434 | 349 | 442 | 586 | 656 | 487 |
| Total Liabilities | 1,154 | 1,274 | 1,521 | 3,192 | 3,145 | 3,146 | 3,114 | 3,322 | 3,193 | 3,274 | 3,569 | 3,708 |
| Fixed Assets | 417 | 403 | 491 | 578 | 810 | 870 | 885 | 990 | 1,257 | 1,252 | 1,301 | 1,214 |
| CWIP | 123 | 238 | 250 | 239 | 92.16 | 330 | 569 | 495 | 147 | 123 | 31.06 | 100 |
| Investments | 41.17 | 14.04 | 14.06 | 904 | 930 | 552 | 393 | 265 | 2.01 | 1.01 | 0.00 | 0.00 |
| Other Assets | 574 | 619 | 765 | 1,472 | 1,311 | 1,393 | 1,268 | 1,571 | 1,786 | 1,896 | 2,238 | 2,393 |
| Inventories | 208 | 231 | 282 | 273 | 339 | 397 | 538 | 600 | 625 | 737 | 990 | 975 |
| Trade receivables | 191 | 219 | 314 | 276 | 435 | 389 | 249 | 494 | 587 | 640 | 776 | 826 |
| Cash & equivalents | 27.03 | 20.02 | 16.01 | 682 | 201 | 234 | 81.98 | 114 | 185 | 158 | 118 | 295 |
| Total Assets | 1,154 | 1,274 | 1,521 | 3,192 | 3,145 | 3,146 | 3,114 | 3,322 | 3,193 | 3,274 | 3,569 | 3,708 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 78.04 | 112 | 67.98 | −112 | −328 | 20.01 | 33.01 | −260 | −85.02 | 13.99 | −7.01 | 4.01 |
| Cash from investing activity | −52.22 | −85.29 | −133 | 1,654 | −287 | −36.12 | −66.23 | 100 | 242 | 63.26 | −243 | 195 |
| Cash from financing activity | −50.80 | −32.88 | 58.79 | −878 | −1.99 | −61.79 | −121 | 190 | −80.74 | −106 | 183 | 1.99 |
| Net cash flow | −25.04 | −7.01 | −4.01 | 656 | −617 | −78.10 | −154 | 32.03 | 75.13 | −29.03 | −65.14 | 200 |
| Capex | 79.29 | 163 | 151 | 160 | 195 | 387 | 289 | 127 | 44.15 | 23.08 | 138 | 123 |
| Free cash flow | 3.99 | −27.96 | −78.89 | −271 | −518 | −359 | −253 | −385 | −123 | 0.00 | −142 | 163 |
| CFO / OP % | 95.0% | 87.0% | −237.1% | 89.0% | 424.0% | −49.0% | 52.0% | −350.0% | 160.0% | 23.0% | 4.0% | 6.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 58 | 60 | 165 | 124 | 135 | 129 | 74 | 142 | 160 | 131 | 135 | 137 |
| Inventory days | 170 | 183 | 396 | 277 | 277 | 373 | 517 | 526 | 413 | 364 | 417 | 348 |
| Days payable | 114 | 131 | 297 | 230 | 182 | 236 | 202 | 161 | 193 | 174 | 164 | 128 |
| Cash conversion cycle | 116 | 113 | 265 | 172 | 231 | 267 | 390 | 508 | 382 | 322 | 389 | 358 |
| Working capital days | 89 | 91 | 175 | 134 | 166 | 155 | 164 | 208 | 208 | 174 | 160 | 170 |
| ROCE % | 9.0% | 15.0% | 9.0% | 128.0% | −2.0% | −2.0% | 2.0% | 1.0% | −5.0% | 0.0% | 6.0% | 4.0% |
For the Jun 2026 quarter, Unichem Laboratories reported sales of ₹632 Cr, up 20.0% year on year and net profit of ₹41.08 Cr. The operating margin was 11.0%.
Unichem Laboratories' sales for the year to Mar 2026 were ₹2,200 Cr; over the last twelve months they were ₹2,304 Cr.
Net profit for the year to Mar 2026 was ₹253 Cr, and ₹304 Cr over the last twelve months. Earnings per share over the same trailing period were ₹43.35.
Unichem Laboratories reported borrowings of ₹500 Cr at Mar 2026, against cash and equivalents of ₹295 Cr.
Cash from operations was ₹4.01 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹163 Cr.